1. Home
  2. PAXS vs CTMX Comparison

PAXS vs CTMX Comparison

Compare PAXS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Access Income Fund of Beneficial Interest

PAXS

PIMCO Access Income Fund of Beneficial Interest

HOLD

Current Price

$15.57

Market Cap

721.4M

Sector

Finance

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.92

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAXS
CTMX
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
721.4M
596.2M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
PAXS
CTMX
Price
$15.57
$4.92
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.86
AVG Volume (30 Days)
162.4K
2.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$138,103,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
36.45
52 Week Low
$13.63
$0.40
52 Week High
$16.56
$6.35

Technical Indicators

Market Signals
Indicator
PAXS
CTMX
Relative Strength Index (RSI) 39.81 43.29
Support Level $15.35 $3.83
Resistance Level $15.64 $6.20
Average True Range (ATR) 0.22 0.33
MACD -0.03 -0.11
Stochastic Oscillator 37.68 10.76

Price Performance

Historical Comparison
PAXS
CTMX

About PAXS PIMCO Access Income Fund of Beneficial Interest

PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: